E1WL34 Stock Overview
Provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$89.73 |
| 52 Week High | US$129.61 |
| 52 Week Low | US$76.40 |
| Beta | 1.13 |
| 11 Month Change | -6.21% |
| 3 Month Change | -30.37% |
| 1 Year Change | 1.73% |
| 33 Year Change | -42.54% |
| 5 Year Change | n/a |
| Change since IPO | 11.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| E1WL34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -3.4% | 0.1% | -1.2% |
| 1Y | 1.7% | 15.7% | 8.2% |
Return vs Industry: E1WL34 underperformed the BR Medical Equipment industry which returned 15.9% over the past year.
Return vs Market: E1WL34 underperformed the BR Market which returned 9.7% over the past year.
Price Volatility
| E1WL34 volatility | |
|---|---|
| E1WL34 Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.2% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: E1WL34's share price has been volatile over the past 3 months.
Volatility Over Time: E1WL34's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 19,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| E1WL34 fundamental statistics | |
|---|---|
| Market cap | R$215.76b |
| Earnings (TTM) | R$8.43b |
| Revenue (TTM) | R$33.97b |
25.6x
P/E Ratio6.4x
P/S RatioIs E1WL34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E1WL34 income statement (TTM) | |
|---|---|
| Revenue | US$6.20b |
| Cost of Revenue | US$1.47b |
| Gross Profit | US$4.74b |
| Other Expenses | US$3.20b |
| Earnings | US$1.54b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.56 |
| Gross Margin | 76.38% |
| Net Profit Margin | 24.82% |
| Debt/Equity Ratio | 8.0% |
How did E1WL34 perform over the long term?
See historical performance and comparison